New York Hospital Queens Recruiting Patients in a Clinical Study for Promising Treatment for Type 2 Diabetes

Thursday, March 25, 2010

FOR IMMEDIATE RELEASE
CONTACTS:
 

Cynthia Bacon, 718-670-2515
David Levine, 212-772-9447

Flushing, N.Y., March 25, 2010– New York Hospital Queens (NYHQ) is actively looking for people with Type 2 diabetes between the ages of 18 to 75 and who take oral agents to control their diabetes to take part in a clinical study of a promising new treatment for diabetes.

The study utilizes a generic drug called salsalate, widely prescribed for arthritis, which has shown early promising results for the treatment of patients with type 2 diabetes.

The results of the first phase of the study, called TINSAL-T2D (for Targeting Inflammation using Salsalate in Type 2 Diabetes), were first reported online on March 16 in the Annals of Internal Medicine.  With continued funding from the National Institute of Diabetes and Digestive and Kidney Diseases, NYHQ was chosen as a study site for the second part of the study, which will evaluate efficacy and safety in a larger group of people over a longer time period than the first phase.

According to government figures, there are an estimated 24 million Americans and 730,000 New Yorkers with Type 2 diabetes.  “Because adults with diabetes are two to four times more likely to have heart disease or suffer a stroke than people without diabetes, the federal government and diabetes researchers have long been interested in finding a safe, effective and inexpensive way to treat diabetes,” says Daniel Lorber, M.D., F.A.C.P., C.D.E, director, NYHQ’s Division of Endocrinology and associate director, The Theresa and Eugene M. Lang Center for Research and Education. Dr. Lorber is a principal investigator for the second phase of TINSAL-T2D.

“This is an intriguing study as it may help us understand the role that inflammation plays in the development of diabetes. We are pleased to be collaborating in this important national study,” notes Dr. Lorber.

People with diabetes who are interested in taking part in this study should call The Lang Center for Research and Education at New York Hospital Queens, (718) 670-2914, for further information.

Background
Salsalate is an atypical non-steroidal anti-inflammatory agent that is chemically similar to aspirin but a bit easier on the stomach. A three-month clinical study of people with type 2 diabetes, led by researchers at the Joslin Diabetes Center in Massachusetts, found that those who took salsalate showed significantly improved blood glucose levels.

Starting off, the patients all had levels of hemoglobin A1C (a standard measurement that reflects blood sugar levels over several months) in the range of 7.0 to 9.5%. A significant number of those who took salsalate saw this number drop by 0.5%, a result that is in the range of several recently released diabetes therapeutics. Other tests related to glucose levels also showed substantial improvement.  However, the researchers cautioned that they do not recommend patients use this medication for their diabetes treatment until further studies are completed.


New York Hospital Queens is a member of the NewYork-Presbyterian Healthcare System and an affiliate of the Weill Medical College of Cornell University.

###

Note to Editors: Dr. Lorber is available for interviews on diabetes and the TINSAL-T2D trial. His special interests include diabetes and all its health care and social aspects. He has held numerous committee positions for a variety of state and national organizations focused on diabetes including the New York Diabetes Association and the American Diabetes Association.  In 2009, the American Diabetes Association awarded Dr. Lorber its “Outstanding Physician Clinician Award” for his years of dedication and research.

 
Connect Healthcare Panacea CMS Solutions
Site Map | Contact Us | Privacy Policy | Term of Use
Copyright © 2014 New York Hospital Queens
56-45 Main Street, Flushing, NY 11355